Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 9/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890372 | 0.88 | P2RY1 (0.37) | P2RY1HDAC1HDAC6EPHX2NOTUM | |
| SCHEMBL4893251 | 0.87 | P2RY1 (0.36) | P2RY1HDAC1HDAC6EPHX2NOTUM | |
| SCHEMBL4760782 | 0.86 | HDAC1 (0.33) | P2RY1HDAC1HDAC6NOTUMRORC | |
| Trifluoroacetic Acid SCHEMBL4762245 | 0.85 | P2RY1 (0.37) | P2RY1HDAC1HDAC6EPHX2 | |
| Trifluoroacetic Acid SCHEMBL4761896 | 0.84 | OPRM1 (0.36) | P2RY1HDAC1HDAC6EPHX2 | |
| SCHEMBL5578587 | 0.84 | SIGMAR1 (0.36) | P2RY1HDAC1HDAC6EPHX2NOTUM | |
| SCHEMBL5579105 | 0.84 | OPRM1 (0.42) | P2RY1 | |
| SCHEMBL4881720 | 0.81 | NOTUM (0.38) | EPHX2NOTUMRORC | |
| SCHEMBL5578616 | 0.80 | NOTUM (0.46) | P2RY1HDAC1HDAC6NOTUM | |
| SCHEMBL4893344 | 0.79 | OPRM1 (0.41) | HDAC1HDAC6EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | claimed |
| EP-1899339-A1 | 1,2-DIHYDRO-SPIRO(3H-INDOLE-3-4 -PIPERIDINE) COMPOUNDS AS MODULATORS OF THE MAS RECEPTOR NOVEL | Arena Pharmaceuticals, Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2007002114-A1 | 1,2-DIHYDRO-SPIRO(3H-INDOLE-3-4’-PIPERIDINE) COMPOUNDS AS MODULATORS OF THE MAS RECEPTOR NOVEL | ARENA PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | AGTR1, AGTR2, AVPR2 | P2RY1 205/4885HDAC1 418/4885HDAC6 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.